Published in PLoS One on December 01, 2010
Inflammation and atherosclerosis. Circulation (2002) 20.77
C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med (2004) 15.30
Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med (2008) 7.33
Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med (2004) 7.12
The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med (2001) 5.50
B-type natriuretic peptide in cardiovascular disease. Lancet (2003) 4.80
Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med (2008) 4.34
N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med (2005) 3.35
Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med (2002) 2.70
Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull (2006) 2.69
Myocardial perfusion scintigraphy: the evidence. Eur J Nucl Med Mol Imaging (2004) 2.41
Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci U S A (1995) 2.00
Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction. Health Technol Assess (2004) 1.82
Increased cardiac BNP expression associated with myocardial ischemia. FASEB J (2003) 1.78
Incremental value of prognostic testing in patients with known or suspected ischemic heart disease: a basis for optimal utilization of exercise technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography. J Am Coll Cardiol (1995) 1.64
Cardiovascular disease and androgens: a review. Int J Cardiol (2009) 1.63
Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis. Arterioscler Thromb Vasc Biol (2005) 1.56
The sex differential in mortality from all causes and ischemic heart disease. Am J Epidemiol (1983) 1.46
Prognostic value of stress Tc-99m tetrofosmin SPECT in patients with previous myocardial infarction: impact of scintigraphic extent of coronary artery disease. J Nucl Cardiol (2004) 1.40
YKL-40--an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol (2009) 1.39
Serum YKL-40 levels in patients with coronary artery disease. Coron Artery Dis (2007) 1.32
N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation (2004) 1.27
YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria. Diabetes Care (2008) 1.23
Confidence intervals for predictive values with an emphasis to case-control studies. Stat Med (2007) 1.21
Prognostic value of poststress left ventricular volume and ejection fraction by gated myocardial perfusion SPECT in women and men: gender-related differences in normal limits and outcomes. J Nucl Cardiol (2006) 1.13
High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J (2009) 1.12
Low grade inflammation as measured by levels of YKL-40: association with an increased overall and cardiovascular mortality rate in an elderly population. Int J Cardiol (2009) 1.11
Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease. Am Heart J (2007) 1.11
YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease. Scand Cardiovasc J (2008) 1.08
Serum levels of YKL-40 increases in patients with acute myocardial infarction. Coron Artery Dis (2008) 1.08
Inflammatory markers, angiographic severity of coronary artery disease, and patient outcome. Am J Cardiol (2007) 1.06
Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation. J Investig Med (2003) 1.04
Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease. Intern Med J (2005) 1.00
Prognostic value of dipyridamole technetium-99m sestamibi myocardial tomography in patients with stable chest pain who are unable to exercise. Am J Cardiol (1994) 0.89
The present role of nuclear cardiology in clinical practice. Q J Nucl Med Mol Imaging (2005) 0.88
B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide - Diagnostic role in stable coronary artery disease. Exp Clin Cardiol (2006) 0.83
B Type natriuretic peptide: a good omen in myocardial ischaemia? Heart (2003) 0.81
C-reactive protein in patients with normal perfusion and mild to moderate perfusion defects who have undergone myocardial perfusion imaging with 99m-Tc sestamibi gated spect. Prilozi (2008) 0.77
Prognostic value of stress-gated Tc-99m sestamibi SPECT after acute myocardial infarction. Am J Cardiol (2001) 0.77
Increased prognostic value of combined myocardial perfusion imaging and exercise electrocardiography in patients with coronary artery disease. J Nucl Cardiol (2000) 0.77
The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med (2004) 3.34
Approved IFCC recommendation on reporting results for blood glucose (abbreviated). Clin Chem (2005) 2.82
Impaired regulation of the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab (2011) 1.90
Female sex is associated with a better long-term survival in patients hospitalized with congestive heart failure. Eur Heart J (2004) 1.65
Increasing incidence of diabetes after gestational diabetes: a long-term follow-up in a Danish population. Diabetes Care (2004) 1.61
Sources of circulating 3,5,3'-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. J Clin Endocrinol Metab (2007) 1.61
Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial. Atherosclerosis (2010) 1.60
A P387L variant in protein tyrosine phosphatase-1B (PTP-1B) is associated with type 2 diabetes and impaired serine phosphorylation of PTP-1B in vitro. Diabetes (2002) 1.57
Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology (2008) 1.47
Erythropoietin over-expression protects against diet-induced obesity in mice through increased fat oxidation in muscles. PLoS One (2009) 1.44
Incidence rate of symptomatic painless thyroiditis presenting with thyrotoxicosis in Denmark as evaluated by consecutive thyroid scintigraphies. Scand J Clin Lab Invest (2013) 1.39
YKL-40--an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol (2009) 1.39
Systolic versus diastolic cardiac function variables during epirubicin treatment for breast cancer. Int J Cardiovasc Imaging (2009) 1.38
YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria. Diabetes Care (2008) 1.23
Approved IFCC recommendation on reporting results for blood glucose: International Federation of Clinical Chemistry and Laboratory Medicine Scientific Division, Working Group on Selective Electrodes and Point-of-Care Testing (IFCC-SD-WG-SEPOCT). Clin Chem Lab Med (2006) 1.23
Increased YKL-40 expression in patients with carotid atherosclerosis. Atherosclerosis (2010) 1.17
High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J (2009) 1.12
Low grade inflammation as measured by levels of YKL-40: association with an increased overall and cardiovascular mortality rate in an elderly population. Int J Cardiol (2009) 1.11
IRS-1 serine phosphorylation and insulin resistance in skeletal muscle from pancreas transplant recipients. Diabetes (2006) 1.10
Increased mortality in patients hospitalized with primary hyperparathyroidism during the period 1977-1993 in Denmark. World J Surg (2003) 1.00
Association of polymorphisms of the CHI3L1 gene with asthma and atopy: a populations-based study of 6514 Danish adults. PLoS One (2009) 0.96
YKL-40 levels are independently associated with albuminuria in type 2 diabetes. Cardiovasc Diabetol (2011) 0.93
Increased levels of the calcification marker matrix Gla Protein and the inflammatory markers YKL-40 and CRP in patients with type 2 diabetes and ischemic heart disease. Cardiovasc Diabetol (2010) 0.91
Prevalence of cachexia in chronic heart failure and characteristics of body composition and metabolic status. Endocrine (2012) 0.91
Variability and reproducibility of hepatic FDG uptake measured as SUV as well as tissue-to-blood background ratio using positron emission tomography in healthy humans. Clin Physiol Funct Imaging (2008) 0.88
Assessment of volume measurement of breast cancer-related lymphedema by three methods: circumference measurement, water displacement, and dual energy X-ray absorptiometry. Lymphat Res Biol (2010) 0.87
Anthracycline-induced chronic cardiotoxicity and heart failure. Acta Oncol (2007) 0.86
Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial. Immunobiology (2012) 0.85
Dietary habits and nutritional status of renal transplant patients. J Ren Nutr (2004) 0.84
The Association between genetic variations of CHI3L1, levels of the encoded glycoprotein YKL-40 and the lipid profile in a Danish population. PLoS One (2012) 0.84
Differential effects of endurance training and weight loss on plasma adiponectin multimers and adipose tissue macrophages in younger, moderately overweight men. Am J Physiol Regul Integr Comp Physiol (2013) 0.84
Increased plasma N-terminal pro-B-type natriuretic peptide and markers of inflammation related to atherosclerosis in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf) (2005) 0.83
Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial. Diagn Microbiol Infect Dis (2010) 0.83
Contemporary methods of body composition measurement. Clin Physiol Funct Imaging (2014) 0.82
Hyperparathyroidism and long-term bone loss after renal transplantation. Clin Transplant (2003) 0.82
The precision and influence of rotation for measurements of bone mineral density of the distal femur following total knee arthroplasty: a methodological study using DEXA. Acta Orthop Scand (2003) 0.82
Serum ionised calcium and cardiovascular disease in 45-years old men and women followed for 18 years. Eur J Epidemiol (2006) 0.81
IFCC guideline for sampling, measuring and reporting ionized magnesium in plasma. Clin Chem Lab Med (2008) 0.81
Similar clinical outcome after unicompartmental knee arthroplasty using a conventional or accelerated care program: a randomized, controlled study of 40 patients. Acta Orthop (2009) 0.81
High YKL-40 levels predict mortality in patients with type 2 diabetes. Diabetes Res Clin Pract (2011) 0.81
Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium. Diabetologia (2014) 0.81
Insulin resistance and maximal oxygen uptake. Clin Cardiol (2003) 0.81
Variations of CHI3L1, levels of the encoded glycoprotein YKL-40 and prediction of fatal and non-fatal ischemic stroke. PLoS One (2012) 0.80
Associations between plasma insulin-like growth factor-I and the markers of inflammation interleukin 6, C-reactive protein and YKL-40 in an elderly background population. Inflamm Res (2010) 0.80
Plasma YKL-40 levels are elevated in patients with chronic heart failure. Scand Cardiovasc J (2010) 0.80
Myocardial perfusion defects and the left ventricular ejection fraction disclosed by scintigraphy in patients with primary hyperparathyroidism. World J Surg (2005) 0.79
Higher prevalence of risk factors for type 2 diabetes mellitus and subsequent higher incidence in men. Eur J Intern Med (2007) 0.79
High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR trial. Scand J Clin Lab Invest (2010) 0.79
Variation in CHI3LI in relation to type 2 diabetes and related quantitative traits. PLoS One (2009) 0.79
Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. J Cardiovasc Pharmacol (2010) 0.79
Increased levels of YKL-40 and interleukin 6 in patients with chronic pancreatitis and secondary diabetes. Pancreas (2012) 0.78
Long-term heart function after adjuvant epirubicin chemotherapy for breast cancer. Acta Oncol (2012) 0.78
Recommendation for measuring and reporting chloride by ISEs in undiluted serum, plasma or blood. Clin Chem Lab Med (2006) 0.78
Gated tomographic radionuclide angiography using cadmium-zinc-telluride detector gamma camera; comparison to traditional gamma cameras. J Nucl Cardiol (2013) 0.78
Cross-talk between the heart and adipose tissue in cachectic heart failure patients with respect to alterations in body composition: a prospective study. Metabolism (2013) 0.77
[Polycystic ovary syndrome and comorbidity]. Ugeskr Laeger (2010) 0.77
Concentrations of the acute phase reactants high-sensitive C-reactive protein and YKL-40 and of interleukin-6 before and after treatment in patients with acromegaly and growth hormone deficiency. Clin Endocrinol (Oxf) (2007) 0.77
N-terminal pro-B-type natriuretic peptide in patients with growth hormone disturbances. Clin Endocrinol (Oxf) (2007) 0.76
Short-term teriparatide treatment does not affect NT-proBNP, a marker of cardiac disease. Scand J Clin Lab Invest (2012) 0.76
[Frequency of osteoporosis in women aged 50-80 years with Colles' fracture]. Ugeskr Laeger (2004) 0.76
Prolonged hypobaric hypoxemia attenuates vasopressin secretion and renal response to osmostimulation in men. J Appl Physiol (1985) (2002) 0.76
Osteoporosis among Fallers without Concomitant Fracture Identified in an Emergency Department: Frequencies and Risk Factors. Adv Orthop (2010) 0.75
Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective? Cardiology (2011) 0.75
High coronary artery calcium score affects clinical outcome despite normal stress myocardial perfusion imaging and normal left ventricular ejection fraction. Coron Artery Dis (2013) 0.75
Impact of vitamin D status and obesity on C-reactive protein in kidney-transplant patients. J Ren Nutr (2008) 0.75
[Where are we going?]. Ugeskr Laeger (2004) 0.75
[Uric acid as a marker of pathophysiological mechanisms in patients with cardiovascular disease]. Ugeskr Laeger (2005) 0.75
Insulinoma in a third-trimester pregnant woman combined with pre-eclampsia: a case report and review of the diagnostic strategies. Gynecol Endocrinol (2008) 0.75
[Mediastinal parathyroid cystadenoma--a rare cause of primary hyperparathyroidism]. Ugeskr Laeger (2006) 0.75
Prospective analysis of a first MTP total joint replacement. Evaluation by bone mineral densitometry, pedobarography, and visual analogue score for pain. Foot Ankle Surg (2011) 0.75
Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: the CLARICOR trial. Scand J Clin Lab Invest (2014) 0.75
The effect of 99mTc on dual-energy X-ray absorptiometry measurement of body composition and bone mineral density. J Clin Densitom (2012) 0.75
Parathyroid scintigraphy during hypocalcaemia in primary hyperparathyroidism. Clin Physiol Funct Imaging (2005) 0.75
Correction: Genome-wide physical activity interactions in adiposity - A meta-analysis of 200,452 adults. PLoS Genet (2017) 0.75
Corrigendum: Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature (2017) 0.75
A suggestion of reference data for flow distribution at ankle and foot level using quantitative 99Tc-HDP three-phase bone scintigraphy. Clin Physiol Funct Imaging (2011) 0.75
Pharmacogenetics and individual responses to treatment of hyperglycemia in type 2 diabetes. Pharmacogenet Genomics (2015) 0.75
[Picture of the month: Meckel's diverticulum]. Ugeskr Laeger (2002) 0.75
[Primary hyperparathyroidism--occurrence, symptoms, complications and treatment]. Ugeskr Laeger (2005) 0.75
Guidelines for sampling, measuring and reporting ionized magnesium in undiluted serum, plasma or blood: International Federation of Clinical Chemistry and Laboratory Medicine (IFCC): IFCC Scientific Division, Committee on Point of Care Testing. Clin Chem Lab Med (2005) 0.75
Determination of kidney function with 99mTc-DTPA renography using a dual-head camera. Nucl Med Commun (2013) 0.75